Vasculitis features in many diseases, making it a complex condition. Aggravation or recurrence is seen in a considerable number of patients receiving conventional treatment of vasculitis. In recent years, biologic agents alone or in combination with other drugs have shown some advantages in treating refractory vasculitis and controlling the recurrence of vasculitis. In 2012, the European League against Rheumatism classified vasculitis into 7 categories. This article mainly reviews the progress in biological agents for the treatment of these 7 categories of vasculitis in recent years with a view to providing reference for clinicians.